Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer

Post time 1 hour(s) ago

journal：Journal of Clinical Oncology

Authors：Dongsheng Yue; Shidong Xu; Qun Wang; Xiaofei Li; Yi Shen; Heng Zhao; Chun Chen; Weimin Mao; Wei Liu; Junfeng Liu; Lanjun Zhang; Haitao Ma; Qiang Li; Yue Yang; Yongyu Liu; Haiquan Chen; Zhenfa Zhang; Bin Zhang; Changli Wang

Published date：2022-12-1

DOI：10.1200/jco.22.00428

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00428

Article link：https://doi.org/10.1200/jco.22.00428

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time 1 hour(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer